|
References
Anthropometrics
| 1. | Devine, Ben. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-6. |
| 2. | Hume R. Prediction of lean body mass from height and weight. J Clin Pathol.1966;19:389–91. |
| 3. | Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17):1098 (letter) |
| 4. | DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Medicine. 1916; 17:863-71. |
| 5. | Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000 Sep;34(9):1066-9. |
| 6. | Rice, TL and Rice, KA. Commonly Used Equations for Estimating Lean Body Weight are Inaccurate. Hospital Pharmacy Volume 36, Number 9, pp 955–961 |
| 7. | Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. |
| 8. | Schwartz, GL. A simple estimate of glomerular filtration rate in children Pediatrics 1976:58:259-263. |
| 9. | Traub SL, Kichen L. Estimating ideal body mass in children. Amer J Hosp Pharm 1983;40:107-10. |
| 10. | Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: A height weight formula validated in infants, children and adults. The Journal of Pediatrics 1978 (93):1:62-66. |
| 11. | Haycock GB, et al. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978;93:62-6. |
| 12. | Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988 Jun;84(6):1053-60. |
| 13. | Jelliffe Roger, et al. Estimation of creatinine clearance in patients with unstable renal function. Math Biosci. 14:17-24 (June) 1972. |
| 14. | Sawyer WT, et al, Variables Affecting Creatinine Clearance Prediction. Am J Hosp Pharm 1983;40:2175-80. |
| 15. | Canaday BR, et al, Fractional Adjustment of Predicted Creatinine Clearance in Females. Am J Hosp Pharm 1984;41:1842-3. |
| 16. | Chow MS, Schweizer R, Estimation of Creatinine Clearance in Patients with Unstable Serum Creatinine Concentrations: Comparison of Multiple Methods. DICP. 1985;19:385-390. |
| 17. | Rhodes PJ, et al: Evaluation of Eight Methods for Estimating Creatinine Clearance in Men. Clin Pharm. 1987;6:399-406. |
| 18. | Drusano GL, et al. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. JAGS 1988;36:437-441. |
| 19. | Lott RS, Hayton WL: Estimation of Creatinine Clearance from Serum Creatinine Concentration - a review. DICP. 1978;12:140-150. |
| 20. | Paap CM, Nahata MC. Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction. J Clin Pharm Ther. 1995 Apr;20(2):67-73. |
| 21. | Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr, Blouin RA. Estimating creatinine clearance in morbidity obese patients. Am J Hosp Pharm. 1981 Jun;38(6):841-4. |
| 22. | Myers GL, Miller GW, Coresh J, et al. Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry 2006;52(1):5-18. |
| 23. | Pierrat A, Gravier E, Saunders C, Caira MV, Ait-Djafer Z, Legras B, Mallie JP. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and MDRD formulas. Kidney Int. 2003 Oct;64(4):1425-36. |
| 24. | Winter MA, Guhr KN, Berg, GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012;32(7):604-612. |
Aminoglycosides
| 1. | Devine, Ben. Gentamicin therapy. DICP 1974;8:650-655. |
| 2. | Sarubbi FA, Hull JW. Gentamicin serum concentrations: pharmacokinetic predicitions. Ann Intern Med 1976;85:183-189. |
| 3. | Sawchuk RJ, Zaske DE, et al. Kinetic model for gentamicin dosing. Clin Pharmacol Ther 1977;21;3:362-369. |
| 4. | Sarubbi FA, Hull JW. Amikacin serum concentrations: predicition of levels and dosage guidelines. Ann Intern Med 1978;89:612-618. |
| 5. | Blouin RA, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979;26:508-513. |
| 6. | Bauer LA, et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharmacy 1980;37:519-522. |
| 7. | Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Tox 1980;18,12:549-553. |
| 8. | Lesar TS, et al. Gentamicin dosing errors with four commonly used nomograms. JAMA 1982;248(10);1190-1193. |
| 9. | Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348. |
| 10. | Matzke GR, Burkle WS, Lucarotti RL. Gentamicin and tobramycin dosing guidelines: an evaluation. DICP 1983;17:425-432. |
| 11. | Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985. |
| 12. | Burton ME, Brater DC, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357, 1985. |
| 13. | Burton ME, Chow MSS, et al. Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin. Clin Pharm 1986;5:143-149. |
| 14. | Zaske DE. "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 331-381. |
| 15. | Schentag JJ, "Aminoglycosides", in Evans W, Schentag J, Jusko J (eds): Applied Pharmacokinetics. San Francisco. Applied Therapeutics, 1986; pp 382-398. |
| 16. | Fant WK. Controversies in antimicrobial therapy: Pitfalls in monitoring aminoglycoside therapy. AJHP 1986:43:641-645. |
| 17. | Chrystyn H. Validation of the use of Bayesian analysis in the optimization of gentamicin therapy. DICP 1988 22:49-53. |
| 18. | Donahue T, Yates DJ. Predictability of aminoglycoside serum levels dosed by a pharmacy protocol. Hospital Pharmacy 1988:23;11-25 |
| 19. | Rodvelt KA, Zokufa H, Rotschafer JC. Aminoglycoside pharmacokinetic monitoring: An integral part of patient care? Clin Pharm 1988:7:608-613. |
| 20. | Okamoto MP, Chi A, et al. Comparison of two microcoputer Bayesian pharmacokinetic programs for predicting serum gentamicin concentrations. Clin Pharm 1990 9:708-11. |
| 21. | Tsubaki T, Chandler MHH. Evaluating new and traditional methods for aminoglycoside dosing with various degrees of renal function. Pharmacotherapy 1994; 14:330-336. |
Vancomycin
| 1. | Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348. |
| 2. | Matzke GR, Kovarik JM, et al. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm 1985;4:311-315. |
| 3. | Lake KS, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340-344. |
| 4. | Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985. |
| 5. | Rybak MJ, Boike SC. Monitoring vancomycin therapy. DICP 1986;20:757-761. |
| 6. | Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmaco 1986;11:257-282. |
| 7. | Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. DICP 1986;20:64-68. |
| 8. | Cheung RP, DiPiro JT. Vancomycin: An Update. Pharmacotherapy 1986;6:153-69. |
| 9. | Matzke GR. "Vancomycin" In: Applied Pharmacokinetics, Second Edition. Spokane, WA: Applied Therapeutics, Inc., 1986. pp 399-436. |
| 10. | Musa DM, Pauly DJ. Evaluation of a new vancomycin dosing method. Pharmacotherapy 1987;7:69-72. |
| 11. | Garrelts JC, Godley PJ, et al. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987;6:795-799. |
| 12. | Rodvold KA, et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-658. |
| 13. | Pyrka RD, Rodvold KA, et al. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Mon 1989 11:45-454. |
| 14. | Ackerman, Bruce H. Evaluation of three methods for determining initial vancomycin doses. DICP 1989;23:123-7. |
| 15. | Healy DP, et al. Vancomycin-induced histamine release and 'red man syndrome' comparison of 1- and 2-hour infusions. Antimicrobial Agents and Chemo 34; 550-554, 1990. |
| 16. | Pryka RD, Rovold KA, Erdman SM. An updated comparison of drug dosing methods part IV:vancomycin. Clin Pharmaco 1991;20:463-76. |
| 17. | Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Farm 1993 12:126-30. |
| 18. | Leader WG, Chandler MH, and Castiglia M. Pharmacokinetic optimisation of Vancomycin therapy. Clin Pharmacokinet 28(4);327-42 1995. |
| 19. | Pou L, Rosell M, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Mon 1996 18:149-153. |
| 20. | Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343-6. |
| 21. | Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988; 32:848–52. |
| 22. | John E. Murphy; David E. Gillespie; Carol V. Bateman. Predictability of Vancomycin Trough Concentrations Using Seven Approaches for Estimating Pharmacokinetic Parameters. Am J Health-Syst Pharm. 2006;63(23):2365-2370. |
| 23. | Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Lodise TP, Lomaestro B, Graves J, Drusano GL. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. |
| 24. | Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82–98. |
| 25. | Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6. Epub 2008 Jan 28. |
| 26. | Vandecasteele SJ and De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney International 77, 760-764 (May 2010). |
Bayesian analysis
| 1. | Sheiner LB, Beal S, Rosenberg B, et al: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26:294. |
| 2. | Sheiner LB, Beal S. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982 71:1344-1348. |
| 3. | Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetic decision making. Clin Pharm 1984 3:525-30. |
| 4. | Yamaoka K, Nakagawa T, et al. A nonlinear multiple regression program based on Bayesian algorithm for microcomputers. J. Pharmacobio-Dyn., 8, 246-256 1985. |
| 5. | Ito M, Duren L, et al. Computer program for the initiation of vancomycin therapy. Clin Pharm 1993 12:126-30. |
| 6. | Burton ME, Brater DC, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37:349-357, 1985. |
| 7. | Jelliffe R. Effect of assumptions concerning assay error patterns upon pharmacokinetic parameter values and model behavior. J. Vet Pharmacol Ther 17:105-109, 1994. |
|
